Document is current

Article History

Accepted: 3 December 2023

First Online: 6 January 2024

Declarations

:

: The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 821520. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

: David J. Lewis is a full-time employee of Novartis Pharma AG and holds shares in GlaxoSmithKline and Novartis. Laura M. Yates provided consultancy for Sanofi Genzyme South Africa on two occasions in 2021 relating to genetic testing in Gaucher’s disease (April 2021, advisory board presentation) and a conference lecture on genetic testing in cardiac clinics (September 2021). Yrea R.J. van Rijt-Weetink, Toine C.G. Egberts, Florence P.A.M. van Hunsel, Ursula Winterfeld and Eugène P. van Puijenbroek have no conflicts of interest that are directly relevant to the content of this article.

: Ethics approval was not needed for this study.

: No approval or consent was needed for this study.

: No approval or consent was needed for this study.

: The datasets for this article are not publicly available because of the data protection policy of Pharmacovigilance Centre Lareb. Requests to access the datasets should be directed to the corresponding author and will be granted on reasonable request.

: The codes for this article are not publicly available because of the data protection policy of Pharmacovigilance Centre Lareb. Requests to access the codes should be directed to the corresponding author and will be granted on reasonable request.

: The original study protocol was designed by YvRW, DL, LY, UW and EvP. Data analysis was performed by YvRW, KC and EvP. The design of the manuscript was determined by YvRW, TE, FvH and EvP. All authors contributed to manuscript drafting and revision. All authors approved the final version to be published and agree to be accountable for all aspects of the work.